September 27, 2008 -- Phynova will adopt a China-centric business plan; Crown Bioscience will build a second China-located CRO facility in Taicang City; Qiagen and the Chinese Academy of Sciences will develop new molecular tests to determine the safety of food; 3SBio filed for SFDA approval of a high-dose formulation of EPIAO; Sinovac Biotech will develop a vaccine for human hand, foot and mouth disease; China Pharma Holdings hopes to report a positive cash flow in Q3; China Sky One Medical increased its full-year 2008 revenue and income guidance; Tianyin Pharma will migrate to the American Stock Exchange; the International Pharmaceutical Excipients Council (IPEC) China was formed at a critical time for the industry; and new reports showed that the coverup of the baby formula scandal started in late 2007. More details...
